[Special Stock] Miko's Subsidiary Receives WHO Support for COVID-19 Test Kits, Strong Overseas Exports

Bangladesh Government Receives WHO Relief Funds and Introduces Miko Diagnostic Kits

[Asia Economy Reporter Minwoo Lee] Miko's stock price is on the rise following news that its subsidiary has successfully exported a novel coronavirus (COVID-19) diagnostic kit overseas.

According to the Korea Exchange on the 18th, as of 9:45 AM, Miko's stock price is up 9.8% from the previous day, reaching 8,400 KRW. This appears to be due to the news that Miko's subsidiary, Mikobiomed, is exporting COVID-19 diagnostic kits to Bangladesh.

Earlier, the bio-medical diagnostic company Mikobio announced on the same day that it will supply a COVID-19 diagnostic system to the government of Bangladesh. To prevent the spread of COVID-19 within the country, the Bangladesh government decided to use relief funds from the World Health Organization (WHO) to conduct tests at emergency testing centers using Mikobiomed's diagnostic products. It is reported that Mikobiomed's equipment has already been installed at these emergency testing centers.

Mikobiomed, which applied for emergency use authorization for its COVID-19 diagnostic system in Korea last January, had already demonstrated the excellence of its products by conducting clinical trials in countries experiencing COVID-19 outbreaks, such as China and the Middle East, even before receiving domestic approval.

This content was produced with the assistance of AI translation services.